AR046919A1 - COMBINATIONS OF A COX INHIBITOR AND A VASOPRESINE RECEIVER ANTAGONIST FOR TREATMENT OF DISMENORREA - Google Patents

COMBINATIONS OF A COX INHIBITOR AND A VASOPRESINE RECEIVER ANTAGONIST FOR TREATMENT OF DISMENORREA

Info

Publication number
AR046919A1
AR046919A1 ARP040103890A ARP040103890A AR046919A1 AR 046919 A1 AR046919 A1 AR 046919A1 AR P040103890 A ARP040103890 A AR P040103890A AR P040103890 A ARP040103890 A AR P040103890A AR 046919 A1 AR046919 A1 AR 046919A1
Authority
AR
Argentina
Prior art keywords
treatment
vasopresine
dismenorrea
combinations
cox inhibitor
Prior art date
Application number
ARP040103890A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR046919A1 publication Critical patent/AR046919A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de una combinacion de (A) un antagonista de la familia del receptor de vasopresina o su derivado farmacéuticamente aceptable y (B) un inhibidor de COX o su derivado farmacéuticamente aceptable para el tratamiento o la profilaxis de la dismenorrea. Producto farmacéutico, composicion farmacéutica y método de tratamiento.Use of a combination of (A) an antagonist of the vasopressin receptor family or its pharmaceutically acceptable derivative and (B) a COX inhibitor or its pharmaceutically acceptable derivative for the treatment or prophylaxis of dysmenorrhea. Pharmaceutical product, pharmaceutical composition and treatment method.

ARP040103890A 2003-10-27 2004-10-26 COMBINATIONS OF A COX INHIBITOR AND A VASOPRESINE RECEIVER ANTAGONIST FOR TREATMENT OF DISMENORREA AR046919A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0325021.4A GB0325021D0 (en) 2003-10-27 2003-10-27 Therapeutic combinations

Publications (1)

Publication Number Publication Date
AR046919A1 true AR046919A1 (en) 2006-01-04

Family

ID=29725435

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103890A AR046919A1 (en) 2003-10-27 2004-10-26 COMBINATIONS OF A COX INHIBITOR AND A VASOPRESINE RECEIVER ANTAGONIST FOR TREATMENT OF DISMENORREA

Country Status (4)

Country Link
AR (1) AR046919A1 (en)
GB (1) GB0325021D0 (en)
TW (1) TW200528095A (en)
WO (1) WO2005039565A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231206B1 (en) * 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
CA2528975A1 (en) * 2003-06-10 2004-12-16 Pfizer Inc. Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea

Also Published As

Publication number Publication date
GB0325021D0 (en) 2003-12-03
WO2005039565A1 (en) 2005-05-06
TW200528095A (en) 2005-09-01

Similar Documents

Publication Publication Date Title
ECSP056229A (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES POLYMODIC FORMS OF 3- (4-AMINO-1-OXO-1.3 DYHIDRO-ISOINDOL-2-IL) -PIPERIDINA-2,6-DIONA FOR THE TREATMENT AND HANDLING OF CANCERES
AR045900A1 (en) GLUCOCORTICOESTEROID COMPOUND, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND ITS USE FOR THE TREATMENT OF INFLAMMATORY AND / OR ALLERGIC DISORDERS.
MX2010006736A (en) Hcv protease inhibitors and uses thereof.
EA200401169A1 (en) AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
ECSP034878A (en) RECEIVER MODULATORS ACTIVATED BY THE PEROXISOM PROLIFERATOR
ECSP056194A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR ITS PREPARATION AND ITS USE AS QUINASA INHIBITORS
BRPI0417717A (en) compound, pharmaceutical composition, and use of a compound
AR058308A1 (en) VIP FRAGMENTS AND METHODS OF USE OF THE SAME
LTPA2013018I1 (en) 4-OXOQUINOLINE COMPOUNDS AND THEIR USE AS HIV INGREGATE INHIBITORS
CL2004000778A1 (en) COMPOUNDS DERIVED FROM 5-MEMBER HETEROCICLES, INHIBITORS OF PORTEIN TIROSINA FOSFATASA 1B (PTP1B); PHARMACEUTICAL COMPOSITIONS, USEFUL TO TREAT HYPERTENSION, OBESITY, DIABETES, HYPERLIPIDEMIA.
UY27668A1 (en) ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
ECSP044992A (en) INHIBITORS OF THE ALQUÍN-ARIL FOSFODIESTERASA-4
ECSP066753A (en) CHEMIOCINE RECEIVER ANTAGONISTS
DE602005014382D1 (en) 2-pyrimidinyl pyrazolopyridine ERBB Kinase Inhibitors
SE0301372D0 (en) Novel compounds
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
NO20052493D0 (en) Selected CGRP antagonists, processes for their preparation and their use as pharmaceutical compositions.
GT200900283A (en) "COMBINATION THERAPY WITH A COMPOUND ACTING AS AN ADP PLAQUETARY RECEPTOR INHIBITOR".
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CR10009A (en) STABILITY CONTROL OF THE DOSAGE FORM OF CC-779 THROUGH THE CONTROL OF SUBSTANCES OF PHARMACO SUBSTANCES
CR7583A (en) NEW VENLAFAXINA O-DESMETIL FORMAMATE SALT
CL2007003100A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINA, INHIBITORS OF CISTEINE PROTEASA; PREPARATION PROCESSES; SALES OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF MALARIA.
EA200801619A1 (en) METHOD OF IMPROVING PHARMACOKINETICS INHIBITORS INHIBITORS HIV (OPTIONS), SET AND PHARMACEUTICAL COMPOSITION (OPTIONS)
AR049274A1 (en) ACID2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS A SELECTIVE KINASE IKK-2 INHIBITOR
CL2007000595A1 (en) Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others.

Legal Events

Date Code Title Description
FB Suspension of granting procedure